Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TYMS | P04818 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29027575 | 1.00 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL29027533 | 0.97 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL30311295 | 0.97 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL24193104 | 0.97 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL24192875 | 0.93 | DHFR (0.68) | DHFR | |
| Talotrexin SCHEMBL30947427 | 0.92 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL1060263 | 0.92 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL29376907 | 0.92 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL31476904 | 0.92 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL1060264 | 0.92 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4457229-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | Byondis B.V. (NL) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023126297-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-07-06 | — | — | WO | disclosed |
| CN-116209476-A | Antifolate linker-drug and antibody-drug conjugates | 拜奥迪斯私人有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | DHFR 1/4885KDM4E 2050/4885MEN1 1545/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | DHFR 1/4885KDM4E 2050/4885MEN1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.